Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were eligible.
Specific interventions included in the review
Studies comparing S. boulardii with placebo or no intervention were eligible for inclusion. The dosage of S. boulardii in the included studies ranged from 250 to 750 mg/day, taken over 5 to 6 days. Three of the included studies were placebo-controlled trials; the remaining studies gave no additional intervention to the control group
Participants included in the review
Studies with children with acute diarrhoea (as defined by the investigators) were eligible. The participants in the included studies were aged between 2 months and 12 years.
Outcomes assessed in the review
The primary outcomes were duration of diarrhoea, stool output, the percentage of children with diarrhoea at set investigator-defined cut-off points, and the percentage of children with diarrhoea lasting over 7 days. The secondary outcomes were stool frequency, vomiting, adherence to treatment, adverse effects and other reported outcomes. Only one included study gave a definition for the termination of diarrhoea.
How were decisions on the relevance of primary studies made?
Three reviewers independently screened the studies, and any discrepancies were resolved by discussion.